We report on a molecular investigation carried out to ascertain the prevalence of drug-resistant tuberculosis (TB) and the specific gene mutations responsible for resistance to rifampicin (RIF) and/or isoniazid (INH) in Iraq. In total, 110 clinical isolates from category II TB cases from Baghdad (58 %) and several Iraqi provinces (42 %) were analysed using colorimetric, low-cost and low-density (LCD) microarrays (MYCO-Direct and MYCO-Resist LCD array kits) to identify the point mutations responsible for resistance in Mycobacterium tuberculosis isolates. We found 76 patients (69.1 %) had resistant strains, of which 40 (36 %) were multidrugresistant (MDR)-TB. Where mono-resistance was identified, it was found to be predominantly to RIF (83 %). The most common mutations were rpoB S531L (50 %), inhA C15T (25 %) and katG S315T (15 %). The most common MDR-TB genotypes were rpoB S531L with inhA C15T (60 %) and rpoB S531L with katG S315T (20 %). Where phenotypic analysis of clinical isolates was also performed, genotypic data were found to show excellent correlation with phenotypic results. Correlation was found between the MYCO-Resist LCD array and GenoType MTBDRplus for detection of resistance to RIF. Our study shows MDR-TB in 36 % of category II TB cases in Baghdad and surrounding Iraqi provinces, which reflects the World Health Organization findings based on phenotypic studies. Diagnosis of TB and MDR-TB using culture-based tests is a significant impediment to global TB control. The LCD arrays investigated herein are easy to use, sensitive and specific molecular tools for TB resistance profiling in resource-limited laboratory settings.
INTRODUCTION
Tuberculosis (TB) is a major cause of mortality, resulting in 2 million deaths globally and 9 million new cases annually (Brudey et al., 2006) . According to the Iraq Ministry for Health, Iraq is ranked 44th globally for TB incidence, but 11th for TB mortality. Iraqi TB cases constitute 3 % of the total cases in the Eastern Mediterranean Region (WHO, 2012b) . Despite widespread application of the World Health Organization (WHO)'s Directly Observed Treatment Strategy for TB control, TB incidence in Iraq has increased since 2003 to 117 per 100 000 population in 2010 (WHO, 2012a; Yousif et al., 2009) . The country has been affected by conflict which has made it difficult to assess the extent of the problem. Whilst TB incidence is high, case detection rates remain low; estimated at 43 % in 2007 43 % in and 49 % in 2010 43 % in (WHO, 2012b . The National Tuberculosis Programme in Iraq aimed to reach and maintain detection of 70 % of infectious TB cases and cure at least 85 % of those cases by 2013, and also to reduce the prevalence of and deaths due to TB by 50 % by 2015 (Iraq Ministry for Health, 2012).
Multidrug-resistant (MDR)-TB, defined as TB showing resistance to at least isoniazid (INH) and rifampicin (RIF), is diagnosed in w400 000 people annually (Frieden et al., 1993; WHO, 2007; Yew & Chau, 1995) and is a major public health problem in Iraq. Previous anti-TB therapy is the most significant predisposing factor for developing MDR-TB (Sharma et al., 2011) . The WHO reported a worldwide MDR-TB rate of 4.3 % of all TB cases in 2004, of which 29.4 % were previously treated cases (Zignol et al., 2006) . During 2010, 3.4 % of new cases and 21 % of previously treated TB cases were confirmed as MDR-TB. The 2014 WHO Global Tuberculosis Report described a worldwide MDR-TB rate of 3.5 % in 2013, and a MDR-TB rate of 3.7 % of new cases and 20 % of retreatment cases in Iraq in the same year (WHO, 2014) . Around 96 % of RIF-resistant Mycobacterium tuberculosis occurs due to mutations in the 81 bp RIF resistance-determining region which encodes the b-subunit of RNA polymerase. The molecular mechanisms of INH resistance are more complex, with w18 genes implicated. The catalaseperoxidase gene (katG) is mutated in 60-70 % of cases. In addition, mutations in inhA (which encodes a reductase used in mycolic acid biosynthesis) is associated with resistance to INH (Aragó n et al., 2006; Rattan et al., 1998) . The prevalence and type of mutations conferring resistance vary depending on geographical location (Sajduda et al., 2004; Sharma et al., 2003) .
Since 2006, extensively drug-resistant TB, defined as TB resistant to one of the fluoroquinolone drugs and to at least one of the three injectable second-line drugs, has been deemed by the WHO to pose a serious global threat to public health, particularly in countries with a high prevalence of human immunodeficiency virus infection.
Detection of mutations that confer resistance using genotypic methods is faster and lower risk than phenotypic drug susceptibility testing (DST), which requires growth of M. tuberculosis that can take up to several weeks (Soini & Musser, 2001) . Commercial (Cinngen) and in-house endpoint PCR methods have been used in Iraq to detect TB; however, molecular studies and evaluation of resistance patterns are rare to date (Abbas & Al-Hamdani, 2009 ). One study carried out in Dohuk, Iraq gave insight into the molecular epidemiology of MDR-TB using spoligotyping to genotype-resistant M. tuberculosis strains (Merza et al., 2010) . In this study with a limited number of 53 Iraqi patients with pulmonary TB, the authors identified MDR-TB in 7.9 % of previously untreated patients and in 46.7 % of previously treated patients. Knowledge of resistance patterns and trends is essential so that appropriate anti-TB treatment can be administered.
Low-cost and low-density (LCD) arrays offer an easy way to detect resistance as minimal laboratory instrumentation is needed. Each chip contains eight identical microarrays separated in to small reaction chambers. The labelled amplicons are hybridized to genus-specific or speciesspecific capture probes of 16-22 nt immobilized on the LCD chip surface in duplicate spots.
The MYCO-Direct LCD array includes two primer pairs with three genus-specific capture probes, two M. tuberculosis complex (MTBC)-specific capture probes and 13 capture probes for mycobacteria other than M. tuberculosis. PCR products of 226 bp result from amplification of the genusspecific internal transcribed spacer. An additional fragment of 125-165 bp from the MTBC-specific insertion element IS6110 is also amplified depending on the species present. Due to the high degree of IS6110 sequence similarity between M. tuberculosis and Mycobacterium bovis, the MYCODirect LCD array does not allow discrimination between these species. The MYCO-Resist LCD array will detect point mutations associated with drug resistance in M. tuberculosis. Triplex PCR results in simultaneous amplification of rpoB, inhA and katG genes to produce amplicons of 158, 210 and 248 bp, respectively. The capture probes for rpoB span a 90 bp region coding for aa 504-534, with six probes representing the WT sequence and 12 probes representing resistance-associated single nucleotide polymorphisms (SNPs). katG probes interrogate codon 315 as the WT sequence and two SNPs associated with INH resistance. inhA probes represent three point mutations associated with resistance at nt 8, 15 and 17 in addition to two probes which bind to the WT 59 non-coding region (Aragon et al., 2006) . The post-PCR protocol takes 45 min, and results are read using a transmission light scanner and analysed using automated software or online (www.chipron.com). Baghdad, Iraq). Direct microscopy for acid-fast bacilli (AFB) using both Ziehl-Neelsen and Auramine Phenol was performed on 110 specimens after sputum pooling and decontamination with 2 % sodium hydroxide and concentration. The sensitivity of the Ziehl-Neelsen stain for AFB detection is regarded as 10 4 c.f.u. ml 21 . In order to improve the sensitivity, fluorescence microscopy was also applied. Three sputum specimens were used for evaluation of each patient as recommended by national guidelines of TB control (Mase
METHODS
An-Najaf ( , 2007) , although recent recommendations from the WHO now indicate that two specimens from the patient are sufficient for diagnosis (Noeske et al., 2009) . Specimens were inoculated on Löw-enstein-Jensen medium prepared to the manufacturer's instructions and incubated at 37 uC 5-10 % CO 2 for 6 weeks.
MIC testing was performed on 22 samples for comparison with genotypic DST results. MIC testing allowed confirmation of antibiotic resistance and establishment of the lowest antibiotic concentration that inhibited the visible growth of the micro-organism after incubation. Colonies were harvested from the culture and put in a sterile tube with an equal amount of sterile distilled water and mixed well, and 1/100 and 1/10 000 dilution of the bacterial suspension were cultivated on Löwenstein-Jensen slants and incubated at 37 uC for up to 2 months. Cultures were checked daily for 1 week, followed by once weekly for 8 weeks.
Genotypic characterization DNA extraction. DNA was extracted from each of the Löwenstein-Jensen slope cultures using a freeze-thaw technique as described previously and purified using a Wizard genomic DNA purification kit (Promega) (Reischl et al., 1994) . Genomic DNA was visualized by agarose gel electrophoresis [GelDoc 1000 (Bio-Rad); PeqPower E300 (PeqLab); GNA100 (Amersham Bioscience)]. Following extraction, DNA was transported from Baghdad to the UK at room temperature. DNA quantity and quality were then measured using a spectrophotometer (NanoDrop).
PCR. Multiplex PCR was performed using the labelled primers provided in the MYCO-Direct 1.7 and MYCO-Resist 3.5 LCD array kits (Chipron) and HotStarTaq DNA Polymerase (Qiagen) as per the manufacturer's instructions. PCR products were visualized by agarose gel electrophoresis and capillary gel electrophoresis using a Bioanalyzer 2100 (Agilent Technologies) for enhanced sensitivity in cases where the product could not be visualized on a standard gel.
Chipron LCD arrays. MYCO-Direct hybridization is suited to testing of sputum samples without the need for culture, providing a rapid identification of mycobacteria. In this study, culture was performed and as a result a small number of samples were tested using the species detection array. MYCO-Resist testing was performed on all 110 samples. Hybridization using MYCO-Direct and MYCO-Resist LCD arrays was carried out as per the manufacturer's instructions. Briefly, biotinylated PCR product was mixed with formamide-based hybridization buffer and 30 ml applied to each LCD array on the chip (Aragó n et al., 2006). The chip was placed on a foam pad inside a humidity chamber (containing 250 ml water). The closed chamber was transferred to a 36 uC water bath for 30 min hybridization. LCD array chips were washed for 2 min in a low-stringency buffer, placed in a Chipron transport container and dried using the centrifugation tool provided. The chips were incubated with 30 ml streptavidin-horseradish peroxidase conjugate for 5 min at room temperature followed by additional wash steps (Aragó n et al., 2006). The container was centrifuged at 1000 r.p.m. for 1 min to dry the chip. After drying, 30 ml substrate was added to each array for 2 min, creating a dark insoluble precipitate where hybridization had taken place. High-resolution greyscale images taken using a transmission light film scanning device were analysed using the software provided.
GenoType MTBDR plus
GenoType MTBDRplus simultaneously identifies MTBC and resistance to RIF and/or INH from cultured isolates or smear-positive pulmonary specimens. PCR products are hybridized to a nitrocellulose strip containing 27 reaction zones including 11 rpoB, katG and inhA WT probes and 10 mutation probes to detect some of the most common mutations that confer resistance. The mutation probes for rpoB are designed to detect D516V (rpoB MUT1), H526Y (rpoB MUT2A), H526D (rpoB MUT2B) and S531L (rpoB MUT3). Two capture probes for the katG gene harbour the sequence for the mutations S315T1 (katG MUT1) and S315T2 (katG MUT2). The capture probes for the inhA promoter region are designed for four point mutations: C15T, A16G, T8C and T8A. Following the manufacturer's instructions, GenoType MTBDRplus analysis was performed on eight DNA samples at SMRL and the results made available for this study.
RESULTS

Iraq TB study panel
The geographical distribution of the 110 patients included in the study is depicted in Fig. 1(a) ; 82 patients (75 %) were from Baghdad or bordering provinces. Patient age ranged from 11 to 70 years, but more than half of the TB cases (56 %) were in the 20-40 years category (Fig. 1b) . TB was slightly more prevalent among males than females LCD genotyping of drug-resistant TB in Iraq included in the study (68 and 32 %, respectively) (Fig. 1c) . All 141 sputum samples were smear-positive using one or both AFB staining methods; 31 specimens were excluded from analysis due to contamination of the Löwenstein-Jensen media or because the mycobacteria failed to grow.
MYCO-Direct and MYCO-Resist LCD arrays
Transport of genomic DNA resulted in loss of DNA integrity in some samples (data not shown). However, the concentration of extracted DNA ranged from 22.5 to 657 ng ml 21 with A 260/280 purity of 1.6-2, which was considered suitable for the study. IS6110 PCR was positive for all 110 samples amplified with MYCO-Direct primers, indicating M. tuberculosis. The 39 samples which were hybridized on MYCO-Direct microarrays yielded a positive result for M. tuberculosis. Some variability was seen in intensity of the colorimetric microarray signals due to differences in the concentration of template DNA used in the PCR.
Hybridization of triplex rpoB, inhA and katG PCR products to the MYCO-Resist LCD array showed that 34 (31 %) MTBC isolates were sensitive to both RIF and INH (Fig. 2) . In total, 75 (69 %) MTBC isolates contained SNP mutations conferring a range of resistance genotypes (Table 1, Fig. 3 ). Mono-resistant strains made up 32 % of isolates tested, of which 83 % were RIF-resistant. The most common mutations found in each resistance gene were rpoB S531L (50 % frequency), inhA C15T (25 %) and katG S315T (15 %). Other SNPs were found at katG S315N (5 %), rpoB L533P (5 %), rpoB H526Y (4 %), rpoB D516V (3 %), rpoB S531W (2 %) and rpoB H526D (2 %). Of the resistant isolates, 40 (36 %) were found to be MDR. The most common MDR-TB genotypes were rpoB S531L with inhA C15T (60 % of the MDR isolates) and rpoB S531L with katG S315T (20 %). A greyscale image showing typical hybridization signals for MDR-TB (clinical isolate 16) using the MYCO-Resist LCD array is shown in Fig. 4 , together with the corresponding colour intensity of the hybridization signal for each feature with SNPs identified at rpoB S513L and inhA C15T.
Comparison of MYCO-Resist LCD array and GenoType MTBDRplus for the detection of resistance to RIF and/or INH RIF resistance or susceptibility was correctly identified in all DNA extracts provided by SMRL based on results of MYCOResist LCD array and the GenoType MTBDRplus analysis. In five of eight (63 %) SMRL samples, mutations identified were concurrent between MYCO-Resist LCD array and GenoType MTBDRplus (Table 2) . A mutation conferring resistance to INH was not detected by the LCD array in two MDR-TB samples, and GenoType MTBDRplus also failed to detect an INH resistance mutation. Another discrepancy was found in one sample due to the identification of an incorrect SNP in inhA. A larger sample number would be required to assess the sensitivity and specificity of both methods, but this was not an aim of this study.
Genotypic compared to phenotypic DST
Where comparison was possible (22 isolates, 20 %), MYCO-Resist results also showed good correlation with phenotypic DST results (Table 1) . Due to the time demands of DST and limited resources, DST analysis of all samples was not undertaken and 20 % of study samples were considered adequate for robust comparison to genotypic data. Using the molecular test, a rpoB mutation was found in 15 clinical isolates which had also been determined to be RIF-resistant by phenotypic methods. Similarly, 10 clinical isolates which were found to be INH-resistant using phenotypic methods gave a positive hybridization signal for an inhA or katG mutation using the MYCO-Resist array. No mutations were found by genotypic analysis in six MTBC which were fully sensitive to both INH and RIF by phenotypic DST. Only one sample (clinical isolate 34) gave a discrepant result. Relative to phenotypic DST analysis, isolate 34 yielded a false-positive result of INH resistance.
DISCUSSION
Diagnosis of TB and MDR-TB, particularly in developing countries, is based on time-consuming, culture-based tests that have been in use for many decades and are a significant impediment to global TB control. Rapid detection of TB drug resistance is critical to patient care, but the turnaround of culture-based DST diminishes their clinical impact. LCD arrays allow more rapid turnaround times and potentially faster initiation of appropriate treatment, which may reduce the spread of TB disease. In Iraq, the emergence of resistance, particularly MDR-TB, has become a major public health problem (WHO, 2012b) . Application of easy-to-use molecular methods, suitable for use in resource-limited laboratory settings, has facilitated clinical evaluation of MDR-TB in samples from Baghdad (58 %) and a broad geographical distribution of Iraqi provinces (42 %). The study yielded data on prevalence which reflects benchmark methods and WHO data, and additional data on the frequency of resistant genotypes.
Our SNP frequency findings are in keeping with those reported around the world. The rpoB S531L SNP is the most common mutation site associated with RIF resistance, but the frequency of other rpoB mutations varies depending on geographical location (Kapur et al., 1994; Mani et al., 2003; Pozzi et al., 1999; Soudani et al., 2007) . rpoB mutations at position H526Y and S512T feature at high frequency in many regions, and this is not seen herein (Cavusoglu et al., 2002; Sajduda et al., 2004 2003). A number of isolates in this study were found to have a SNP at inhA C15T. This mutation has also been reported in various geographical locations, but is considered responsible to a lesser extent for INH resistance (Bakonyte et al., 2003; Jiao et al., 2007; Wu et al., 2006) . Frequency distribution findings for the SNPs identified in our study are corroborated in many European genotypic MDR-TB studies (Hillemann et al., 2005; Sajduda et al., 2004) . MDR-TB resistance profiles and prevalence identified herein are similar to other findings in the WHO Eastern Mediterranean Region. For example, in Saudi Arabia, SNP frequencies and incidence of MDR-TB levels are also similar at 39 %, although a different population was tested (Nimri et al., 2011) . A recent genotypic study in Jordan found rpoB S531, rpoB D516, rpoB H526 and katG to be of highest frequency, with the incidence of MDR-TB at 6 % based on newly diagnosed TB cases. Similar SNP frequency distribution findings were reported in Iran (Khosravi et al., 2012) . According to the WHO, MDR-TB is found in 8.1 % (Turkey), 9 % (Saudi Arabia), 26 % (Syria), 29 % (Iran) and 48 % (Jordan) of category II TB cases (WHO, 2012c) . Our study shows MDR-TB in category II TB cases in Iraq to be amongst the highest prevalence in countries in the region.
In conclusion, the MYCO-Resist LCD array was successfully employed to identify the frequency of specific rpoB, katG and inhA mutations that confer resistance in Iraqi category II TB cases. The test is simple, cost-effective and rapid. Results showed widespread occurrence of mono-resistant genotypes and MDR-TB. A genotypic study of this nature provides insight into drug resistance patterns for this region in which prevalence of drug-resistant TB is an ongoing problem. 
